Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome
"The FDA regulates brand-name GLP-1 drugs such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) and approves those drugs in very specific doses," says Katy Williams, MD, an MU Health Care family medicine doctor and bariatric medicine specialist
Long-term safety data continues to accumulate, and a comprehensive 2024 review in Diabetes Care by Daniel Drucker concluded that the overall risk-benefit profile of GLP-1 medicines remains favorable for their approved indications
Reducing the risk of cardiovascular problems such as stroke and hypertension in patients with type 2 diabetes and existing heart diseases
May cause liver damage
Academic researchers analyzed a World Health Organization database that tracks suspected adverse drug reactions, and found that there was a 45% greater rate of reports of suicidal thoughts associated with semaglutide, the ingredient in Novo Nordisks Ozempic and Wegovy, compared with all other drugs in the database